The UK government is planning to change the Pharmaceutical Price Regulation Scheme (PPRS) but whatever happens it will remain a voluntary agreement, Richard Barker, director general of the Association of the British Pharmaceutical Industry (ABPI) told journalists.
The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that seven products be approved for sale in Europe, including two biosimilar medicinal products and one generic.
TopoTarget A/S of Denmark, whose founders and managers are clinical cancer specialists, has launched its first product on the US market. The product, Totect, is a treatment for patients who experience a specific type of accident during chemotherapy.
The French Senate has approved the London Agreement, which reduces the translation requirements for patents in Europe.
Pronova BioPharma ASA, a Norwegian company that develops and sells omega-3 derived drugs, has completed an initial public offering (IPO) of its shares on the Oslo Stock Exchange worth about NOK 2.7 billion or €352 million.
Clinicians and representatives of industry say that the requirements for conducting clinical trials in the European Union need to be altered so that the cost of doing research is reduced.
A new UK public-private partnership called Stem Cells for Safer Medicines is asking research-oriented firms to join it in an investigation of whether stem cells can be used to determine the safety of medicines under development.
Aitua Ltd, which provides seed money and early stage investments in life science companies, has invested £50,000 in ViraBiotech Ltd, a spin-out from the University of Warwick in the UK. An equal amount is being invested by the Spinner Matched Investment Fund, a partnership between Warwick and other universities in the West Midlands.
Market conditions for initial public offerings (IPOs) by biotech companies are about the same in Europe as they are in the United States, according to a survey of 200 biotech and investment executives.
Vernalis Plc and its partner Endo Pharmaceuticals Inc have been told by the US Food and Drug Administration that their proposed treatment for the prevention of menstrual migraine has not yet demonstrated a clinically meaningful benefit.